Medicenna Therapeutics Corp.
MDNA.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 849.20K | 952.80K | 1.11M | 989.60K | 941.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.84M | 4.19M | 4.03M | 3.97M | 3.98M |
| Operating Income | -3.84M | -4.19M | -4.03M | -3.97M | -3.98M |
| Income Before Tax | -3.58M | -3.04M | -3.13M | -3.55M | -3.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.58M | -3.04M | -3.13M | -3.55M | -3.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.58M | -3.04M | -3.13M | -3.55M | -3.56M |
| EBIT | -3.84M | -4.19M | -4.03M | -3.97M | -3.98M |
| EBITDA | -3.84M | -4.19M | -4.03M | -3.97M | -3.97M |
| EPS Basic | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 |
| Normalized Basic EPS | -0.03 | -0.02 | -0.02 | -0.03 | -0.03 |
| EPS Diluted | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 |
| Normalized Diluted EPS | -0.03 | -0.02 | -0.02 | -0.03 | -0.03 |
| Average Basic Shares Outstanding | 86.64M | 83.42M | 83.42M | 83.41M | 82.52M |
| Average Diluted Shares Outstanding | 86.64M | 83.42M | 83.42M | 83.41M | 82.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |